Essential Tremor

Clinical Snapshot

Essential tremor (ET) is the most common movement disorder encountered in primary care.^[1] It is classically a bilateral, largely symmetric action tremor — present when the arms are held against gravity (a postural tremor) or during a goal-directed movement such as reaching, writing, or drinking from a cup (a kinetic tremor) — most often affecting the hands and forearms, though the head, voice, and, less commonly, the legs can also be involved.^[1] It affects roughly 4% of adults, with prevalence increasing with age.^[1]

A genuinely useful, distinctive historical clue is transient improvement with alcohol — many patients report that 1-2 drinks noticeably quiet the tremor. This should prompt a specific, non-judgmental screen for alcohol dependency as a form of self-treatment, rather than being taken only as a diagnostic curiosity.^[2]^[1] A family history of the same tremor is common and clinically useful: essential tremor is familial in roughly 75% of cases, though its genetics remain incompletely understood — only four genes with rare causative mutations have been identified to date (FUS, NOTCH2NLC, HTRA2, TENM4), and these are rarely found in typical essential tremor patients.^[3]

Despite decades of study, no single cause has been identified, and essential tremor is now formally classified as a syndrome rather than a single disease with one known etiology.^[3] It is thought to arise from abnormal oscillatory activity generated within the cerebello-thalamo-cortical network — a circuit implicated in tremor generation broadly, not specifically diagnostic of essential tremor on its own. Purkinje cell pathology has been reported on post-mortem study in some, but not all, essential tremor cases and is not considered a uniform or pathognomonic finding.^[3]

The single most consequential judgment call in this chapter is distinguishing essential tremor from Parkinson's disease tremor. Essential tremor is an action tremor — present with movement or sustained posture, and classically quiet at rest — that is usually bilateral (though often asymmetric in severity) and occurs without bradykinesia, rigidity, or postural instability. Parkinson's disease tremor is classically a resting tremor — present when the limb is fully supported and relaxed, and improving with voluntary action — that is usually asymmetric at onset and accompanied by the other cardinal features of parkinsonism. Treating one as the other delays the correct diagnosis and the correct treatment; see Recognize the Condition for the full bedside comparison.

Recognize the Condition

Typical presentation

Essential tremor most often begins in the hands, presenting as a fine-to-moderate amplitude tremor that is absent or minimal at rest and becomes visible with a sustained posture (arms outstretched) or during a task requiring fine motor control — eating, writing, drinking from a cup, or fastening buttons. Severity is often asymmetric between the two hands even though onset is bilateral. Head tremor (a "yes-yes" or "no-no" pattern) and voice tremor can occur in isolation or alongside limb tremor and, for some patients, are the more functionally and socially disabling feature.^[1]

Essential tremor vs. Parkinson's disease tremor — the key bedside distinction

Feature	Essential tremor	Parkinson's disease tremor
Tremor type	Action (postural and/or kinetic) — present with sustained posture or movement	Rest tremor — present when the limb is fully relaxed and supported; improves with voluntary action
Distribution at onset	Bilateral, often asymmetric in severity	Unilateral at onset
Alcohol response	Often transiently improves with 1-2 drinks	Typically unresponsive to alcohol
Associated signs	None — no rigidity or bradykinesia; arm swing preserved while walking	Cogwheel rigidity, bradykinesia, reduced arm swing, shuffling gait, postural instability
Handwriting	Large and tremulous	Small (micrographia)
Head/voice involvement	Can occur as head tremor or voice tremor	Uncommon; a resting "pill-rolling" chin tremor may occur instead
Family history	Often positive	Often absent
Finger-to-nose testing	Tremor amplitude stays the same or increases as the finger approaches the target	Tremor amplitude diminishes or disappears as the finger approaches the target

^[2]^[4]

A second useful bedside maneuver: ask the patient to count backward, or perform another distracting cognitive task, while the arms rest in the lap — a Parkinsonian resting tremor typically re-emerges or worsens with the distraction, while essential tremor, which is not present at rest to begin with, remains unchanged.^[4]

Other tremor phenotypes and mimics to screen for

Reversible and secondary causes

Enhanced physiologic tremor

A reversible, fine, high-frequency postural/kinetic tremor occurring without underlying neurologic disease, triggered by anxiety, caffeine, or alcohol/sedative-hypnotic withdrawal, and by specific drugs — amiodarone, amphetamines, beta-adrenergic agonists (including bronchodilators), lithium, thyroid hormone, tricyclic antidepressants, and valproic acid are recognized causes — along with excessive caffeine intake (more than 2-3 eight-ounce cups of coffee per day, or the equivalent from chocolate or soft drinks).^[4]^[2] Correcting the underlying trigger is itself the treatment; a dedicated essential-tremor drug is not needed.^[4]

Thyrotoxicosis

Enhances adrenergic activity and produces a similar fine action tremor; screen with thyroid function testing as part of the standard workup (see Assessment & Diagnosis) before attributing a new tremor to essential tremor.^[4]^[2]

Dystonic tremor and cerebellar (intention) tremor

Distinguished by their association with dystonic posturing, or with ataxia and dysmetria respectively — these findings change management and should prompt specialist referral rather than a first-line essential-tremor drug trial.

Diagnostic criteria and "essential tremor plus"

Current international consensus classification — used here to define the syndrome precisely, alongside the Canadian clinical sources this chapter otherwise draws from — defines essential tremor as an isolated tremor syndrome: a bilateral upper-limb action tremor of at least 3 years' duration, with or without tremor in other locations (head, voice, or lower limbs), and without other neurological signs such as dystonia, ataxia, or parkinsonism.^[3] When mild additional findings of uncertain significance are present — impaired tandem gait, questionable dystonic posturing, memory impairment, or a rest tremor superimposed on the action tremor — the syndrome is instead classified as essential tremor plus. These soft signs do not, on their own, justify a different diagnosis, but they should prompt closer follow-up, since some of these patients go on to develop a different or additional movement disorder over time.^[3]

Risk Factors

Family history — essential tremor is familial in roughly 75% of cases, though only a small number of specific causative gene mutations have been identified, and confirmatory genetic testing is rarely informative in routine practice.^[3]
Age — prevalence increases with advancing age.^[1]
Reversible or exacerbating factors that mimic or worsen tremor, and should be screened for in every new patient: excess caffeine intake, anxiety, alcohol or sedative-hypnotic withdrawal, and a specific list of tremorogenic drugs — amiodarone, amphetamines, beta-adrenergic agonists (including bronchodilators), lithium, thyroid hormone, tricyclic antidepressants, and valproic acid.^[4]^[2]
Thyrotoxicosis, other metabolic/endocrine disturbances, and hepatic or renal dysfunction can each produce or worsen a postural tremor and should be excluded before attributing new tremor to essential tremor.^[2]
No clear environmental or lifestyle risk factor beyond the above has been consistently identified; the underlying etiology of essential tremor itself remains unknown despite extensive study, and it is now understood as a syndrome rather than a single disease.^[3]

Red Flags & Refer

Any of the following changes the plan from "start or adjust an essential-tremor drug" to "reassess the diagnosis, correct a reversible cause, or refer":

Unilateral onset, a resting tremor, or tremor accompanied by bradykinesia, rigidity, reduced arm swing, or gait/postural instability — these suggest Parkinson's disease or another parkinsonian syndrome rather than essential tremor and warrant neurology referral rather than an essential-tremor drug trial.^[2]^[1]
Rapid progression over weeks to months — atypical for essential tremor, which is usually slowly progressive over years, and should prompt referral rather than reassurance.^[2]
Additional neurological findings beyond the "soft signs" of essential tremor plus — ataxia, dysmetria, cognitive decline, or overt dystonic posturing — warrant specialist assessment for an alternative or additional diagnosis.^[3]
Significant, persistent functional impairment (difficulty eating, writing, dressing, or working) despite an adequate trial of first- and second-line oral pharmacotherapy — refer for consideration of botulinum toxin or a neurosurgical procedure (deep brain stimulation or focused ultrasound thalamotomy) rather than continuing to escalate oral doses indefinitely.^[1]
New or worsening tremor in a patient recently started on, or with a dose increase of, a known tremorogenic drug (lithium, valproic acid, amiodarone, a beta-agonist bronchodilator, a tricyclic antidepressant, or thyroid hormone) — a pharmacist-actionable finding; discuss the causative drug and dose with the prescriber before assuming essential tremor has simply worsened on its own.^[4]^[2]
Voice or head tremor causing significant social or occupational impairment that has not responded to oral therapy — a specific indication to consider botulinum toxin, which can be effective for this phenotype even when limb tremor is not the dominant problem.^[1]

Assessment & Diagnosis

Essential tremor is a clinical diagnosis

There is no laboratory test or imaging study that confirms essential tremor; the diagnosis rests on the history and examination findings described in Recognize the Condition, and investigations exist mainly to exclude a secondary or reversible cause rather than to "confirm" essential tremor itself.^[2]

Standard workup

Thyroid function testing (TSH) — to exclude thyrotoxicosis as a cause of enhanced physiologic tremor.^[2]^[4]
Liver and renal function testing — hepatic or renal dysfunction can itself produce a postural tremor.^[2]
A complete medication and substance history — caffeine intake, alcohol use pattern (including a specific, non-judgmental screen for dependency given the alcohol-responsiveness clue above), and a directed review for tremorogenic drugs (amiodarone, amphetamines, beta-agonists, lithium, thyroid hormone, tricyclic antidepressants, valproic acid).^[4]^[2]
Neuroimaging is not routinely required for a typical presentation; reserve it for atypical features — unilateral onset, rapid progression, or additional neurological signs — where an alternative diagnosis is genuinely in question.^[2]

Examination

Observe the tremor with the arms outstretched (postural) and during a target-directed task such as finger-to-nose testing or drinking from a cup (kinetic); ask the patient to write a sentence and draw a spiral to characterize amplitude and pattern. Examine gait specifically for reduced arm swing, shuffling, or postural instability, and examine tone for cogwheel rigidity — their presence points away from essential tremor and toward parkinsonism.^[2] On finger-to-nose testing, essential tremor amplitude stays the same or increases as the finger approaches the target, while a Parkinsonian resting tremor typically diminishes with the same movement.^[4]

Applying the diagnostic criteria

Apply the framework from Recognize the Condition: a bilateral upper-limb action tremor of at least 3 years' duration, without other neurological signs, meets criteria for essential tremor; the presence of rest tremor or other soft neurological signs of uncertain significance reclassifies the picture as essential tremor plus rather than a different diagnosis outright.^[3]

Treatment Targets

Reduce tremor amplitude and its functional impact — not eliminate the tremor entirely. No available drug is expected to abolish essential tremor, and at best, pharmacotherapy reduces tremor amplitude by roughly half in about half of treated patients.^[5]
Treat only when there is genuine functional impairment — difficulty writing, eating, drinking, dressing, or working, or significant social embarrassment — not simply because tremor is detectable on examination; many patients with mild essential tremor need no drug therapy at all.^[2]
Address reversible contributors first — caffeine, alcohol, and tremorogenic drugs — before or alongside starting a dedicated essential-tremor drug.^[4]^[2]
Correctly confirm the diagnosis (essential tremor rather than Parkinson's disease or another parkinsonian syndrome) before choosing therapy, since the two conditions are treated differently.^[2]
Minimize medication burden, particularly in older adults, where the sedating, cognitive, and fall-risk profile of several of these agents becomes disproportionately important.
Preserve function and quality of life as the outcome that matters most — track a patient's actual ability to write, eat, drink, or work, not only visible tremor amplitude.

Choose Initial Treatment

Direct treatment rule

Confirm the diagnosis and functional impairment, then choose propranolol or primidone first

Propranolol and primidone both carry the strongest (Level A) evidence for essential tremor and are considered equally effective first-line options.^[6]^[1] The choice between them is driven mainly by comorbidities and tolerability, not by superior efficacy of one over the other. Preferred first-line if no contraindication propranolol, given its more predictable, better-tolerated titration. Preferred first-line if a beta-blocker is contraindicated, or if propranolol was inadequate primidone, provided it is started at a genuinely low dose to avoid its characteristic first-dose reaction.

Propranolol

Situational/performance tremor only 20 mg PO once, 30-60 minutes before an anticipated tremor-provoking event.^[2] Regular use, initial 10-20 mg PO twice daily; titrate at approximately 4-week intervals as tolerated to a usual effective range of 120-320 mg/day in divided doses.^[2]^[5] A long-acting formulation (60-80 mg PO once daily, increased to twice daily as needed) can be substituted once an effective immediate-release dose is established, for patients who prefer once-daily dosing.^[2] Avoid or use with real caution asthma or COPD (nonselective beta-blockade carries a genuine bronchospasm risk), decompensated heart failure, marked bradycardia or high-grade heart block, and significant depression.^[2] Expect fatigue, bradycardia, hypotension, headache, and dizziness; monitor heart rate and blood pressure through titration.^[5]

Primidone

Initial a genuinely low starting dose — 62.5 mg PO at bedtime — is the single most important prescribing point for this drug.^[2] Increase weekly as tolerated toward an initial target of 125 mg PO twice daily, and further to 250 mg twice daily if needed and tolerated, though adverse effects usually limit dose increases beyond this range.^[2] The characteristic risk an idiosyncratic acute sedation, dizziness, nausea, and ataxia reaction can occur with the very first dose or during early titration — particularly in older adults — and is the reason to start low and titrate slowly rather than at a standard maintenance dose.^[2]^[5] For patients on warfarin, primidone induces hepatic metabolism and can lower the INR — monitor closely after starting or adjusting the dose.^[2]

Second-line or add-on: topiramate and gabapentin

If propranolol and primidone are contraindicated, not tolerated, or inadequate topiramate, starting at 12.5-25 mg PO once daily and increasing gradually over several weeks to a target of 25-50 mg PO twice daily.^[2] Watch for paresthesia, word-finding difficulty or cognitive slowing, weight loss, and dizziness/imbalance; stop immediately if a rash develops.^[2] Topiramate is contraindicated in angle-closure glaucoma and should be used cautiously in patients with a history of nephrolithiasis.^[2] An alternative or add-on with inconsistent trial results gabapentin, starting at 300 mg PO once to three times daily (lower in older adults or renal impairment) and titrating as tolerated; published trials studied doses from 1200 to 3600 mg/day, but response is inconsistent across studies and monotherapy benefit is only Level B evidence.^[6]^[5]

Situational or performance tremor

For predictable, situation-specific tremor (public speaking, a specific occupational task) rather than constant functional impairment a single dose of alprazolam or clonazepam taken 30-60 minutes beforehand is a reasonable alternative to PRN propranolol, particularly when anxiety is a clear trigger.^[6] Avoid routine daily benzodiazepine use given the real risk of dependence, sedation, and cognitive impairment — especially in older adults, where these risks compound with fall risk (see Special Populations).

Refractory tremor

Predominantly hand/limb tremor, or voice tremor, inadequately controlled despite an adequate trial of oral agents botulinum toxin injection, individualized to the affected muscles by kinematic or clinical assessment and re-treated at approximately 16-week intervals; expect a genuine risk of grip or finger weakness with limb injection, which tends to emerge over repeated treatments and should be reassessed and, if needed, addressed by dose reduction at each visit (see Pharmacologic Treatment Options and the drug table).^[7]^[8] Severely disabling, medication-refractory limb tremor refer for deep brain stimulation of the ventral intermediate thalamic nucleus, or for MRI-guided focused ultrasound thalamotomy — an incisionless option Health Canada approved for unilateral essential tremor treatment in 2016, pioneered in Canada at Sunnybrook.^[1]^[9] Both procedures are Level C evidence and are decided and performed by a movement disorders/neurosurgical team, not initiated in primary care.^[6]

Non-Pharmacologic Treatment

Reduce or eliminate caffeine — more than 2-3 eight-ounce cups of coffee per day, or the equivalent from chocolate or soft drinks, is enough to provoke or worsen tremor in susceptible patients.^[2]
Review alcohol use specifically, and screen for dependency if a patient reports using alcohol to control tremor — a recognized self-treatment pattern in essential tremor that needs to be addressed directly rather than left unspoken.^[2]
Review and, where feasible, adjust or substitute tremorogenic drugs with the prescriber — amiodarone, amphetamines, beta-agonist bronchodilators, lithium, thyroid hormone, tricyclic antidepressants, and valproic acid.^[4]
Occupational therapy and adaptive strategies for patients with meaningful functional impairment — weighted or built-up utensils, wrist weights, adaptive writing aids, and voice-dictation software for patients with disabling hand tremor.
Manage anxiety and stress, which commonly amplify essential tremor, through the patient's usual supports or referral as appropriate.
Set realistic expectations from the outset: essential tremor typically progresses slowly over years, and the goal of any intervention is meaningful functional improvement, not elimination of the tremor.^[5]
For patients of reproductive potential considering pregnancy: discuss the reproductive-risk profile of topiramate and primidone specifically, and review contraception, before conception where possible (see Special Populations).

Pharmacologic Treatment Options

Drug / intervention	Role	Dose / use	Important adverse effects	Teaching points
Propranolol Preferred	First-line, if no contraindication	10-20 mg PO twice daily, titrated over several weeks to 120-320 mg/day; or 20 mg PRN 30-60 min before a situational trigger	Fatigue, bradycardia, hypotension, headache, dizziness	Level A evidence, equally effective to primidone; avoid in asthma/COPD, decompensated heart failure, marked bradycardia, or significant depression
Atenolol Alternative	Beta-blocker alternative if propranolol's nonselectivity is a concern	50-150 mg PO once daily, titrated to response	Fatigue, bradycardia, hypotension	Level B evidence — less robust than propranolol; a cardioselective option, though still used cautiously in bronchospastic disease
Primidone Preferred	First-line, especially if a beta-blocker is contraindicated	Start 62.5 mg PO at bedtime; titrate weekly to 125 mg twice daily as tolerated (up to 250 mg twice daily)	Acute first-dose sedation, dizziness, nausea, and ataxia (start low, go slow); INR changes with warfarin	Level A evidence, equally effective to propranolol; not currently a published, listed drug in this platform's Drug Database
Topiramate Alternative	Second-line if first-line agents are contraindicated, not tolerated, or inadequate	Start 12.5-25 mg PO once daily; titrate to 25-50 mg PO twice daily	Paresthesia, word-finding difficulty/cognitive slowing, weight loss, dizziness/imbalance, rash	Level B evidence; contraindicated in angle-closure glaucoma; dose-related increased oral-cleft risk with first-trimester exposure
Gabapentin Alternative	Add-on or alternative with inconsistent trial results	Start 300 mg PO once to three times daily; titrate as tolerated (trials studied 1200-3600 mg/day)	Sedation, dizziness, peripheral edema	Level B evidence as monotherapy, but benefit is inconsistent across trials; renally cleared — reduce dose substantially in renal impairment
Alprazolam Special situation	Situational/performance tremor, taken before an anticipated trigger	0.125-3 mg/day in divided doses, or a single dose 30-60 min before the trigger	Sedation, cognitive impairment, dependence with regular use	Level B evidence; reserve for situational use rather than routine daily dosing, especially in older adults
Clonazepam Special situation	Situational/performance tremor, alternative to alprazolam	0.5-6 mg/day in divided doses	Sedation, cognitive impairment, dependence with regular use	Level C evidence; same situational-use caveat and dependence/sedation burden as alprazolam
OnabotulinumtoxinA Special situation	Refractory limb or voice tremor despite adequate oral therapy	Individualized dosing by muscle (limb: ~185 U divided across ~9-10 muscles; voice: low-dose thyroarytenoid injection), re-treated roughly every 16 weeks	Finger/hand/grip weakness, which tends to build over repeated treatments (limb); breathy voice or mild dysphagia (voice)	Level C evidence; reassess strength/voice quality and adjust the dose at every re-treatment visit

Special Populations

Older adults

Older adults are more sensitive to primidone's sedative and ataxic effects — start at the lowest available dose and titrate even more slowly than in younger adults, with close attention to fall risk.^[2] Beta-blockers require extra caution given the higher prevalence of bradycardia and conduction disease in this age group. Benzodiazepines (alprazolam, clonazepam) carry a disproportionate burden in older adults — sedation, cognitive impairment, and a well-established contribution to fall risk — and should not be a first choice for routine, non-situational use.^[6] Reassess the ongoing need for any essential-tremor drug periodically, since polypharmacy and cumulative CNS burden become increasingly important with age.

Pregnancy and breastfeeding

Topiramate carries a specific, quantified risk first-trimester topiramate exposure is associated with an increased risk of oral clefts — reported at roughly 1.4% of exposed infants versus about 0.4-0.7% in unexposed or other-antiepileptic-exposed comparison groups in a large North American pregnancy registry analysis — with a dose-response relationship (higher risk at doses above 100 mg/day).^[10] Confirm reliable contraception before starting topiramate in a patient of reproductive potential, and discuss alternatives specifically before a planned pregnancy.^[10] Primidone is metabolized to phenobarbital, an antiepileptic drug with its own recognized teratogenic risk profile, and should generally be avoided in pregnancy where an alternative is feasible. Propranolol is generally preferred over these alternatives if drug therapy is genuinely needed during pregnancy, used at the lowest effective dose with the prescriber's involvement. Benzodiazepines should be avoided close to delivery given the risk of neonatal sedation and withdrawal. Discuss the benefit-risk balance of any essential-tremor drug in pregnancy and breastfeeding directly with the prescriber, since dedicated safety data for this specific indication are limited for most agents.

Children and adolescents

Essential tremor can begin in childhood but is uncommon; given its rarity in this age group, a new childhood tremor should generally prompt pediatric neurology referral to confirm the diagnosis before assuming essential tremor rather than another cause. Where drug therapy is used, propranolol is the most established option, dosed and titrated by a specialist; primidone and topiramate are less well studied in children for this specific indication.

Renal impairment

Gabapentin is renally cleared and requires a substantial dose reduction in renal impairment. Topiramate is partially renally cleared and should be dose-reduced in significant impairment. Primidone and its active metabolite phenobarbital are partly renally eliminated — use caution and monitor closely. Propranolol is predominantly hepatically metabolized and generally needs little renal adjustment.

Hepatic impairment

Propranolol undergoes extensive first-pass hepatic metabolism — reduce the dose or extend dosing intervals in significant hepatic impairment. Primidone's conversion to phenobarbital is hepatically mediated; use a lower starting dose and titrate with particular caution in hepatic impairment.

Comorbid depression, asthma, or COPD

Avoid propranolol in patients with asthma or COPD (nonselective beta-blockade carries a genuine bronchospasm risk) and use it cautiously, or choose an alternative, in patients with significant depression, since lipophilic beta-blockers can worsen mood symptoms.^[2] Primidone or topiramate are reasonable first-choice alternatives in either situation.

Monitoring & Follow-Up

Reassess each new agent after a full 8-12 week trial at an adequate, tolerated dose before judging it a success or a failure — this is the interval used in the underlying Canadian titration pathway this chapter follows, and moving on too early risks abandoning a drug before it has had a fair trial.^[2]

Monitor heart rate and blood pressure through propranolol titration. Monitor closely for the acute first-dose sedation/ataxia reaction with primidone, particularly in older adults, and check INR in patients on warfarin after starting or adjusting the dose.^[2] With topiramate, monitor weight, cognitive/word-finding symptoms, and ask specifically about visual symptoms (angle-closure glaucoma) and flank pain (nephrolithiasis).^[2] Track the outcome that actually matters to the patient — functional status and quality of life, not only visible tremor amplitude — at every follow-up visit.^[5]

Essential tremor is a progressive condition; even a well-controlled patient may need dose adjustment over subsequent years rather than assuming an initially effective regimen will remain adequate indefinitely.^[5] For patients on botulinum toxin, reassess grip strength (limb tremor) or voice quality (voice tremor) at every re-treatment visit and adjust the dose downward if weakness or breathiness becomes functionally limiting, since this is a genuine, expected risk that tends to build over repeated treatments rather than a rare idiosyncratic one.^[7] For patients who have undergone deep brain stimulation or focused ultrasound thalamotomy, ongoing device or outcome follow-up is managed by the treating neurosurgical/neurology team.

Treatment Failure / Next Step

Inadequate response to the first agent after a full 8-12 week trial at an adequate, tolerated dose: switch to the other first-line agent (propranolol to primidone, or vice versa) rather than immediately combining the two, unless a specific contraindication already dictated the first choice.^[2]
Partial response to first-line monotherapy: combining propranolol and primidone is a reasonable next step before moving to second-line agents, since the two act through different mechanisms.
First-line agents contraindicated, not tolerated, or inadequate even in combination: move to topiramate or gabapentin as described in Choose Initial Treatment.^[6]
Situational/performance tremor not adequately controlled with as-needed dosing: consider a scheduled low-dose regimen only if impairment has become more than purely situational — otherwise keep therapy PRN rather than converting to routine daily use.
Persistent functional impairment despite an adequate, optimized combination of oral agents: reassess the diagnosis first — specifically re-examine for new asymmetry, bradykinesia, or rigidity that would suggest an evolving parkinsonian syndrome rather than treatment-refractory essential tremor — then refer for botulinum toxin (focal hand or voice tremor) or neurosurgical evaluation (deep brain stimulation or focused ultrasound thalamotomy) for disabling limb tremor.^[2]^[1]
Botulinum toxin with declining benefit or new functional weakness: reassess muscle selection and dose at the next scheduled re-treatment rather than simply repeating the same regimen, and reduce the dose if weakness has become functionally limiting.^[7]

Common Errors to Avoid

Treating tremor found incidentally on examination, without genuine functional impairment — many patients with mild essential tremor need no drug therapy at all.^[2]
Diagnosing essential tremor without checking thyroid function or reviewing the medication list for reversible causes.^[2]^[4]
Missing the Parkinson's disease differentiation — treating an asymmetric resting tremor with bradykinesia or rigidity as essential tremor delays the correct diagnosis and referral.^[2]^[1]
Starting primidone at a standard maintenance dose instead of a genuinely low starting dose — this is the single most common way to trigger the acute first-dose sedation/ataxia reaction and undermine adherence before the drug has had a real chance to work.^[2]
Prescribing propranolol without confirming the patient does not have asthma, COPD, decompensated heart failure, marked bradycardia, or significant depression.^[2]
Treating benzodiazepines as a safe, routine first-line option — particularly in older adults, where sedation, cognitive impairment, and fall risk are disproportionate.^[6]
Moving to a new agent before completing a genuine 8-12 week trial at an adequate, tolerated dose of the current one.^[2]
Overlooking topiramate's contraindication in angle-closure glaucoma, its nephrolithiasis risk, and its dose-related oral-cleft risk in pregnancy.^[2]^[10]
Ordering neuroimaging routinely for a typical essential tremor presentation — it is not required unless atypical features are present.^[2]
Forgetting the caffeine/alcohol/medication review as a first, genuinely low-cost step before escalating to drug therapy.^[4]^[2]

Clinical Decision Algorithm

Algorithm A — Recognize and classify

New tremor presentation

Screen for reversible/secondary causes: caffeine, alcohol, tremorogenic drugs (amiodarone, amphetamines, beta-agonists, lithium, thyroid hormone, tricyclic antidepressants, valproic acid); check TSH, liver/renal function^[4]^[2]

Secondary cause identified

Enhanced physiologic tremor, thyrotoxicosis, or another reversible cause — correct the underlying trigger; a dedicated essential-tremor drug is not needed^[4]

Resting tremor, unilateral onset, bradykinesia, rigidity, or reduced arm swing/postural instability

Suspect Parkinson's disease or another parkinsonian syndrome — refer to neurology rather than starting essential-tremor therapy^[2]^[1]

Bilateral action tremor, no parkinsonian features, at least 3 years duration

Apply essential tremor diagnostic criteria; screen for soft neurological signs (impaired tandem gait, questionable dystonic posturing, memory impairment) or rest tremor superimposed on the action tremor^[3]

Essential tremor (or essential tremor plus, if soft signs/rest tremor are present) — go to Algorithm B if functional impairment justifies drug therapy^[3]

Algorithm B — First-line pharmacotherapy

Essential tremor confirmed, with genuine functional impairment

No contraindication to a beta-blocker

Propranolol: 10-20 mg PO twice daily, titrated over several weeks to 120-320 mg/day (or a long-acting once-daily formulation once effective)^[2]^[5]

Beta-blocker contraindicated (asthma/COPD, decompensated heart failure, marked bradycardia, significant depression)

Primidone: start 62.5 mg PO at bedtime, titrate weekly to 125 mg twice daily as tolerated (up to 250 mg twice daily) — go low and slow to avoid the first-dose sedation/ataxia reaction^[2]^[5]

Purely situational/performance tremor

PRN propranolol 20 mg, or PRN alprazolam, 30-60 minutes before the anticipated trigger^[2]^[6]

Reassess after a full 8-12 week trial at an adequate, tolerated dose before judging response^[2]

Adequate response

Continue and periodically reassess; essential tremor is progressive and the dose may need adjustment over time^[5]

Inadequate response or not tolerated

Switch to the other first-line agent (propranolol to primidone, or vice versa), or add/switch to topiramate or gabapentin — see Choose Initial Treatment and Algorithm C

Algorithm C — Escalation for refractory or inadequately controlled disease

Persistent functional impairment despite an adequate trial of first-line therapy (alone or combined) and second-line agents

Re-confirm the diagnosis — re-examine specifically for emerging asymmetry, bradykinesia, or rigidity before assuming this is simply treatment-refractory essential tremor^[2]

Predominantly hand/limb tremor, or voice tremor

Botulinum toxin injection, individualized to the affected muscles and re-treated at approximately 16-week intervals; monitor for grip/finger weakness (limb) or breathy voice (voice tremor), which can build over repeated treatments^[7]^[8]

Severely disabling, medication-refractory limb tremor, unilateral treatment acceptable

Refer for MRI-guided focused ultrasound thalamotomy — an incisionless, Health Canada-approved option for unilateral essential tremor since 2016^[9]

Severely disabling, medication-refractory tremor, bilateral disease or a deep brain stimulation candidate

Refer for deep brain stimulation of the ventral intermediate thalamic nucleus^[1]

Drug Tables

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Beta-Blockers — First-Line (Propranolol) and Alternatives

Propranolol is the preferred first agent given the strongest evidence base; the alternatives below are reasonable substitutes when propranolol specifically is not tolerated, not when a beta-blocker in general is contraindicated.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Propranolol	Situational/PRN: 20 mg PO once, 30-60 minutes before an anticipated trigger Regular, initial: 10-20 mg PO twice daily Regular, titrated: 120-320 mg/day in divided doses Long-acting: 60-80 mg PO once daily, may increase to twice daily	Fatigue, bradycardia, hypotension, headache, dizziness	Additive bradycardia/hypotension with other rate-slowing or antihypertensive drugs; may mask hypoglycemia symptoms in diabetes	Level A evidence, equally effective to primidone; avoid in asthma/COPD, decompensated heart failure, marked bradycardia, or significant depression.
Atenolol	Adults: 50-150 mg PO once daily, titrated to response	Fatigue, bradycardia, hypotension	Additive bradycardia/hypotension with other rate-slowing drugs	Level B evidence, less robust than propranolol; a cardioselective option occasionally preferred for that reason, though still used cautiously in bronchospastic disease.
Sotalol	Adults: 75-200 mg PO twice daily, titrated to response and QT interval	QT prolongation, bradycardia, fatigue	Avoid with other QT-prolonging drugs	Level B evidence; QT-prolongation risk makes this a less preferred alternative, reserved for propranolol-intolerant patients without cardiac risk factors.
Nadolol	Adults: 40-120 mg PO once daily	Fatigue, bradycardia, hypotension	Additive bradycardia/hypotension with other rate-slowing drugs	Level C evidence; long half-life allows convenient once-daily dosing.

Primidone and Anticonvulsants

Primidone is co-first-line with propranolol; topiramate and gabapentin are reasonable second-line or add-on options when first-line agents are contraindicated, not tolerated, or inadequate.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Primidone	Initial: 62.5 mg PO at bedtime Titration: Increase weekly toward 125 mg PO twice daily, as tolerated Maximum: Up to 250 mg PO twice daily if tolerated; adverse effects usually limit further increases	Acute first-dose sedation, dizziness, nausea, and ataxia (start low, go slow, especially in older adults)	Induces hepatic metabolism — monitor INR closely in patients on warfarin; additive CNS depression with other sedating drugs	Level A evidence, equally effective to propranolol; not currently a published, listed drug in this platform's Drug Database.
Topiramate	Initial: 12.5-25 mg PO once daily Titration: Increase gradually to 25-50 mg PO twice daily	Paresthesia, word-finding difficulty/cognitive slowing, weight loss, dizziness/imbalance; rash (stop immediately)	May reduce efficacy of estrogen-containing contraceptives at higher doses; additive CNS effects with other sedating drugs	Level B evidence; contraindicated in angle-closure glaucoma, used cautiously in nephrolithiasis; dose-related increased oral-cleft risk with first-trimester exposure.
Gabapentin	Initial: 300 mg PO once to three times daily, lower in older adults or renal impairment Titration: Trials studied 1200-3600 mg/day in divided doses	Sedation, dizziness, peripheral edema	Additive CNS depression with other sedating drugs; absorption reduced by antacids	Level B evidence as monotherapy, but benefit is inconsistent across trials; renally cleared — reduce dose substantially in renal impairment.

Benzodiazepines — Situational or Performance Tremor

Reserve for predictable, situation-specific tremor rather than routine daily use, given genuine dependence, sedation, and (particularly in older adults) fall-risk concerns.

Drug	Dosage	Adverse effects	Drug interactions	Comments
Alprazolam	Situational/regular: 0.125-3 mg/day in divided doses, or a single dose 30-60 minutes before a trigger	Sedation, cognitive impairment, dependence with regular use, withdrawal on abrupt discontinuation	Additive CNS depression with other sedating drugs, opioids, or alcohol	Level B evidence; use situationally (before a specific anticipated trigger) rather than as routine daily therapy.
Clonazepam	Regular: 0.5-6 mg/day in divided doses	Sedation, cognitive impairment, dependence with regular use, withdrawal on abrupt discontinuation	Additive CNS depression with other sedating drugs, opioids, or alcohol	Level C evidence; an alternative to alprazolam with the same situational-use caveat.

Botulinum Toxin — Refractory Limb or Voice Tremor

Reserve for tremor that remains functionally disabling despite an adequate trial of oral pharmacotherapy. Dosing is individualized by muscle involvement (limb) or by titrated laryngeal injection (voice); reassess strength or voice quality and adjust the dose at every re-treatment visit.

Drug	Dosage	Adverse effects	Drug interactions	Comments
OnabotulinumtoxinA	Limb tremor, initial: Individualized; published protocols average approximately 185 U divided across 9-10 forearm/wrist/elbow/shoulder muscles Limb tremor, re-treatment: Approximately every 16 weeks, with dose adjusted to strength and response Voice tremor: Low-dose thyroarytenoid muscle injection, individualized (published series average roughly 5 U total per treatment)	Finger/hand/grip weakness with limb injection, which tends to build over repeated treatments and is generally reversible with dose reduction; breathy voice or mild dysphagia with laryngeal injection	Additive effect with aminoglycosides or other neuromuscular-blocking drugs	Level C evidence; kinematically-guided limb dosing has shown meaningful, sustained tremor reduction over 96 weeks of repeated treatment, with weakness the main dose-limiting effect.

References

Essential tremor — CMAJ (Schwindt G, Rezmovitz J). CMAJ 2017;189(44):E1364
Enhanced Primary Care Pathway: Essential Tremor — Alberta Health Services, Calgary Zone — Specialist LINK, Primary Care Networks, and Clinical Neurosciences Calgary. AHS Calgary Zone Enhanced Primary Care Pathway, October 2016
The MDS consensus tremor classification: The best way to classify patients with tremor at present — Journal of the Neurological Sciences (Latorre A, Hallett M, Deuschl G, Bhatia KP). J Neurol Sci 2022;435:120191
A patient with tremor, part 2: from diagnosis to treatment — CMAJ (Kumar H, Jog M). CMAJ 2011;183(14):1612-1616
Medications for essential tremor — Canadian Family Physician (Paige A, Moe SS). Can Fam Physician 2026;72(2):112
Evidence-based guideline update: Treatment of essential tremor. Report of the Quality Standards Subcommittee of the American Academy of Neurology — Neurology (Zesiewicz TA, Elble RJ, Louis ED, et al.). Neurology 2011;77(19):1752-1755, reaffirmed 2025
Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics — Canadian Journal of Neurological Sciences (Samotus O, Kumar N, Rizek P, Jog M). Can J Neurol Sci 2018;45(1):11-22
Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor — Journal of Voice (Orbelo DM, Duffy JR, Borst BJH, Ekbom D, Maragos NE). J Voice 2014;28(1):123-127
New clinical trial at Sunnybrook for bilateral essential tremor treatment with focused ultrasound — Sunnybrook Research Institute. Sunnybrook Research, December 2020
Comparative safety of antiepileptic drugs during pregnancy — Neurology (Hernandez-Diaz S, Smith J, Shen A, et al., North American AED Pregnancy Registry). Neurology 2012;78(21):1692-1699

Professional reference only. Apply clinical judgment and verify patient-specific decisions against current authoritative guidance and product information.